A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02841748 |
|
Recruitment Status :
Active, not recruiting
First Posted : July 22, 2016
Last Update Posted : March 6, 2023
|
Sponsor:
University of Chicago
Information provided by (Responsible Party):
University of Chicago
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Active, not recruiting |
|---|---|
| Estimated Primary Completion Date : | June 20, 2025 |
| Estimated Study Completion Date : | June 25, 2025 |